Norihiko Nakano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Norihiko Nakano has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Chizuka Ide
Aino Institute of Regeneration and Rehabilitation, Aino University, 4-5-4 Higashiohda, Ibaraki, Osaka 567-0012, Japan
2 shared publications- Chizuka Ide
Central Biomedical Laboratory, Aino University School of Health Science, 4-5-11 Higashiohda, Ibaraki City, Osaka 567-0012, Japan
2 shared publications Hideki Ohno
Department of Molecular Predictive Medicine and Sport Science; Third Department of Internal Medicine, Kyorin University, School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611; Department of Biochemistry, Sapporo Medical University School of Medicine, South-1 West-17, Chuo-ku, Sapporo 060-8556; and Laboratory of Molecular Medicinal Sciences, Department of Bioscience and Bioinformatics, College of Information Science and Engineering, Ritsumeikan University, Kusatsu, Shiga 525-8577, Japan
2 shared publications- Takako Kizaki
Department of Molecular Predictive Medicine and Sport Science, Kyorin University School of Medicine, 6-20-2 Shinkawa, Mitaka, Tokyo 181-8611, Japan
2 shared publications Yoshiyasu Nakai
Institute of Regeneration and Rehabilitation, Aino Univ., Ibaraki, Japan
2 shared publicationsAtsuo Yamanaka
Translational Research Informatics Center, Foundation for Biomedical Research and Innovation, Kobe, Japan
1 shared publication
Latest Publications
- 1 March 2019
- Published by Elsevier in Brain Research
- Vol. 1707, 208-215
Structures of filum terminale and characteristics of ependymal cells of its central canal in rats
- 1 March 2019
- Published by Elsevier in Brain Research
- Vol. 1707, 208-215
Structures of filum terminale and characteristics of ependymal cells of its central canal in rats
- 1 May 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 622, 88-94
NTAK/neuregulin-2 secreted by astrocytes promotes survival and neurite outgrowth of neurons via ErbB3
- 1 May 2016
- Published by Elsevier in Neuroscience Letters
- Vol. 622, 88-94
NTAK/neuregulin-2 secreted by astrocytes promotes survival and neurite outgrowth of neurons via ErbB3
- 19 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e338
Analysis of bone marrow stromal cell transplantation for spinal cord injury in the rat
- 19 August 2011
- Published by Elsevier in Neuroscience Research
- Vol. 71, e338
Analysis of bone marrow stromal cell transplantation for spinal cord injury in the rat
- 1 October 2010
- Published by Elsevier in Neuroscience Letters
- Vol. 483 (1) , 57-61
Characterization of conditioned medium of cultured bone marrow stromal cells
- 1 October 2010
- Published by Elsevier in Neuroscience Letters
- Vol. 483 (1) , 57-61
Characterization of conditioned medium of cultured bone marrow stromal cells
- 10 September 2007
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 142 (5) , 639-645
Gliclazide Inhibits Proliferation but Stimulates Differentiation of White and Brown Adipocytes
Gliclazide, a second-generation sulfonylurea, has anti-oxidant properties as well as hypoglycemic activities. In the present study, we investigated whether gliclazide affected proliferation and/or differentiation of HW white and HB2 brown adipocyte cell lines. Gliclazide inhibited proliferation of HW and HB2 cells in the medium containing fetal calf serum or epidermal growth factor (EGF). Gliclazide inhibited phosphorylation of EGF receptor and of extracellular signal-regulated kinase (ERK) 1/2 stimulated by EGF. Gliclazide increased lipid accumulation and peroxisome proliferator-activated receptor γ (PPARγ) expression in the early stage of differentiation of adipocytes. A KATP channel activator, diazoxide, did not inhibit the increase of lipid accumulation by gliclazide. Furthermore, gliclazide inhibited the DNA-binding activity of PPARγ in mature adipocytes. On the other hand, glibenclamide, other sulfonylurea, did not show these effects. These results indicate gliclazide inhibits proliferation and stimulates differentiation of adipocytes via down-regulation of the EGFR signalling. Gliclazide may have preventive and therapeutic effects on obesity, as well as on type 2 diabetes.
- 10 September 2007
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 142 (5) , 639-645
Gliclazide Inhibits Proliferation but Stimulates Differentiation of White and Brown Adipocytes
Gliclazide, a second-generation sulfonylurea, has anti-oxidant properties as well as hypoglycemic activities. In the present study, we investigated whether gliclazide affected proliferation and/or differentiation of HW white and HB2 brown adipocyte cell lines. Gliclazide inhibited proliferation of HW and HB2 cells in the medium containing fetal calf serum or epidermal growth factor (EGF). Gliclazide inhibited phosphorylation of EGF receptor and of extracellular signal-regulated kinase (ERK) 1/2 stimulated by EGF. Gliclazide increased lipid accumulation and peroxisome proliferator-activated receptor γ (PPARγ) expression in the early stage of differentiation of adipocytes. A KATP channel activator, diazoxide, did not inhibit the increase of lipid accumulation by gliclazide. Furthermore, gliclazide inhibited the DNA-binding activity of PPARγ in mature adipocytes. On the other hand, glibenclamide, other sulfonylurea, did not show these effects. These results indicate gliclazide inhibits proliferation and stimulates differentiation of adipocytes via down-regulation of the EGFR signalling. Gliclazide may have preventive and therapeutic effects on obesity, as well as on type 2 diabetes.